Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | IL2 | P60568 | 3/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 10/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | DLK1 | P80370 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799671 | 0.97 | MAPK8 (0.43) | MAPK8MAPK9MAPK10IL2MAP4K1 | |
| SCHEMBL12652268 | 0.85 | MAPK8 (0.33) | MAPK8MAPK9MAPK10IRAK4 | |
| SCHEMBL1801507 | 0.83 | MAPK8 (0.64) | MAPK8MAPK9MAPK10IL2MAP4K1 | |
| SCHEMBL1801506 | 0.83 | MAPK8 (0.64) | MAPK8MAPK9MAPK10IL2MAP4K1 | |
| SCHEMBL1798968 | 0.82 | MAP4K1 (0.45) | MAPK8IL2MAP4K1MAP3K12DLK1 | |
| SCHEMBL1798565 | 0.80 | MAPK8 (0.62) | MAPK8MAPK9MAPK10IL2MAP4K1 | |
| SCHEMBL1798563 | 0.80 | MAPK8 (0.62) | MAPK8MAPK9MAPK10IL2MAP4K1 | |
| SCHEMBL1801284 | 0.79 | BRD4 (0.34) | — | |
| SCHEMBL12652241 | 0.78 | MAPK8 (0.30) | MAPK8MAPK9MAPK10MAP3K12 | |
| SCHEMBL2753432 | 0.76 | MAPK8 (0.66) | MAPK8MAPK9MAPK10IRAK4PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | MAPK8 33/4885MAPK9 27/4885MAPK10 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.